Thiourea Derivatives: A Promising Class Against HIV/TB Co-Infection by Marcus Vinicius Nora de Souza et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
7 
Thiourea Derivatives: A Promising Class 
Against HIV/TB Co-Infection 
Marcus Vinicius Nora de Souza1,2, Marcelle de Lima Ferreira Bispo1,2,  
Raoni Schroeder Borges Gonçalves1,2 and Carlos Roland Kaiser2 
1Fundação Oswaldo Cruz (Fiocruz)- Instituto de Tecnologia em  
Fármacos – Farmanguinhos 
2Programa de Pós-Graduação em Química, Instituto de Química,  
Universidade Federal de Rio de Janeiro,  
Brazil 
1. Introduction 
Nowadays, the Human Immunodeficiency Virus (HIV), which is the causative agent of  
Acquired Immune Deficiency Syndrome (AIDS),  represents a serious public health 
problem. According to the World Health Organization (WHO), in 2009 there were 33.3 
million  people living  with HIV worldwide, and more particularly in sub-Saharan Africa, 
where the overwhelming majority  (67%) of cases appear.  Furthermore, 2.6 million people 
have been  recently infected with the virus in 2009,  when HIV/AIDS was estimated to have 
caused  1.8 million deaths  (United Nations Program on HIV/AIDS [UNAIDS], 2010).  
Due to the  impairment of their  immune system,  HIV bearers  are more susceptible to 
opportunistic infections, such as Tuberculosis (TB), which is a leading cause of HIV-related 
deaths worldwide. The risk for TB is 20-37-fold  greater among HIV-infected individuals, 
depending on the  status of the HIV epidemic. According to WHO, one-third of people 
living with  HIV are infected with TB, and there was an estimate of  1.4 million new TB cases 
per year  among said population.  Moreover, one in four TB deaths occurs in HIV-positive 
patients, while  TB was responsible  for 23% of AIDS-related deaths (WHO, 2010a).  
This situation becomes  especially alarming in view of the number of  challenges in  the 
control and management of TB in HIV-infected  individuals, such as the difficulties to 
conclude a TB  diagnosis, as well as  the complexity involved in the  treatment of HIV 
infection-related TB. Due to their great relevance to the subject matter of this work, the  
above factors will be emphasized  in the next section.  
2. Challenges in the management of HIV infection-related TB    
2.1 Diagnosis of TB in HIV-infected individuals  
Within the context of lung diseases,  there are some aspects that may constitute a bar to the 
diagnosis of TB (Box 1): HIV-infected patients are minimally symptomatic or asymptomatic, 
as they present few or less specific classic symptoms of TB (productive cough, chest pain, 
fever, night sweats, weight loss, hemoptysis); patients with low CD4+ T lymphocyte counts 
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have atypical chest radiograph findings, with lower prevalence of cavitary disease, while 
the findings could be normal in  up to 22% of HIV-infected  individuals; the main method 
used worldwide for  TB detection, namely  the microscopic examination of Ziehl-Neelsen-
stained sputum smears, has low sensitivity among HIV-infected  individuals, as they 
develop  acid-faster smear negative diseases with higher frequency than  HIV-uninfected 
people (Sterling et al., 2010).  
Furthermore, HIV-infected individuals present more often the subclinical form of  TB,  said 
factor leading to a delay in the  diagnosis  and treatment. Another  difficulty for the  TB 
diagnosis in HIV-infected individuals is the increased risk (10-20% in HIV-uninfected 
individuals, compared to 40-80% in HIV-infected  persons) to develop extrapulmonary TB, 
whose  most prevalent forms are pleural effusion, lymphadenopathy, pericardial disease, 
miliary disease, meningitis and disseminated TB (Chaisson et al., 1987).  
 
 
2.2 TB treatment in HIV bearers  
In addition to  diagnostic difficulties,  the treatment of HIV infection-related TB also 
presents several challenges, such as duration and frequency,   determining the precise 
moment to start  antiretroviral therapy (ART), management of drug interactions, as well as 
several side effects from therapy. 
As regards the  duration of TB therapy, WHO recommends a 6-month rifampicin-based 
treatment (2HRZE/4HR, Table 1), applying  to both HIV-infected and uninfected  
individuals. Nevertheless, Perriens and  collaborators showed that, after providing a  12-
month therapy with 2HRZE/4HR,   the recurrence rate at the 18th  month shall be lower 
than those observed at  the standard regime (Perriens et al., 1995). Furthermore, another 
study performed by Fitzgerald et al indicated that the administration of isoniazid for 1 year 
upon termination of the therapy under  standard regime reduces the recurrence of TB only 
among HIV-infected patients (Fitzgerald et al., 2000). It is  worthy to mention that, in both 
studies,  patients  had no access to antiretroviral therapy, which  contributes to extend the 
beneficial effects from TB treatment, without presenting the  risks that are inherent to the 
combination of TB-HIV drugs.  
 
Phase Duration (months) Dosing Frequency Drugs 
Intensive 2 Daily HRZE 
Continuous 4 Daily or three times per weeka HR 
a For the continuation phase, the optimal dosing frequency may be also daily; should the administration 
of such a dosage be impossible,  three times per week is a suitable alternative. 
H = isoniazid, R= rifampicin, Z = pyrazinamide, E= ethambutol 
Table 1. TB treatment  for HIV bearers, as recommended by WHO. 
Box 1. Usual difficulties involved in the diagnosis of TB in HIV-infected individuals  
 Minimally symptomatic or asymptomatic patients; 
 Atypical chest radiograph findings; 
 Acute prevalence of acid--fast smear negative disease ; 
 High frequency of subclinical TB form; 
 Increased risk of development of extrapulmonary TB. 
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Providing another relevant  instruction on TB treatment in HIV-infected patients, WHO also 
recommends a daily TB therapy within, at least,  the intensive phase (WHO, 2010b). Such 
orientation  is based on a recent study, which showed that the incidence of relapse and 
failure among HIV-positive TB patients who were treated with intermittent TB therapy 
throughout treatment was 2–3 times higher, in comparison with patients who received a 
daily intensive therapy (Kahn et al., 2010). Moreover, another study indicated that, among  
HIV-positive patients, the risk of acquired resistance to rifampicin  is higher when failing a 
three times weekly short-course intermittent regime (Kahn et al., 2010).  
In relation to HIV treatment (Box 2), WHO recommends that the first-line ART regime 
should comprise a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) 
and one non-nucleoside reverse transcriptase inhibitor (NNRTI), as  said drugs are effective, 
available at low costs in the market,  and present  generic and fixed-dose combinations 
(FDCs). Therefore,  protease inhibitors (PIs) should be kept for second-line regimes (WHO, 
2010b). 
 
 
AZT= zidovudine, TDF= tenofovir,  3TC= lamivudine, FTC= emtricitabine, EFV= efavirenz , NVP= 
nevirapine.  
2.3 Optimal timing to start the ART treatment 
A critical issue among HIV-infected individuals diagnosed with  TB is to determine the 
precise moment to initiate  ART. Although ART improves the survival of  HIV-positive 
patients, including those with TB, the optimal deadline from the onset of TB to start such a 
treatment is a matter that still requires further clarification. According to WHO, the  TB 
treatment should be initiated  in all HIV bearers  showing active TB disease, regardless of 
their CD4+ lymphocyte count. TB treatment should be started first, and, then, followed by 
ART as soon as possible, and preferably  within the first weeks from the beginning of the  
TB treatment (WHO, 2010b). However, the concomitant treatment of both diseases results in 
several disadvantages,  whose examples are listed  and discussed  at the Table 2. 
In spite of a number of clinical trials intended to determine the  optimal timing for ART 
administration in bearers of  HIV infection-related TB,  the question still requires further 
studies  (Piggot & Karakousis, 2011). Among the above referred works,  Abdool Karim and  
collaborators have been performing the Starting Antiviral Therapy at Three Points in TB 
(SAPIT), which is an open-label, randomized and controlled trial conducted in Durban, 
Box 2. Combined regime for  both HIV and TB treatment. 
 First-line regime: 2NRTIs + 1NNRTI  
 [AZT or TDF] and [3TC or FTC] plus [EFV or NVP]; 
 ART regime containing EFV is preferred, since interactions with anti-TB drugs 
are minimal; 
 EFV should not be administrated to  women during  the first trimester 
pregnancy, due to its teratogenic effects . 
  In cases of EFV intolerance,  of  HIV resistant to EFV, or contraindications  to an 
EFV-based regime: [AZT + 3TC + NVP] or TDF + [3TC or FTC] + NVP or the triple 
NRTI regime [AZT + 3TC + ABC] or [AZT + 3TC + TDF] 
 ART regime containing a boosted protease inhibitor (PIs) 
 If available, a rifabutin-based TB treatment should be preferable. 
 Hepatitis among healthy adults is recurrent. 
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South Africa, with 642 HIV-positive patients with a CD4 count <500/mm3 and with smear-
positive TB (Abdool et al., 2010). The preliminary findings of SAPIT showed a decreased 
mortality rate among individuals  who had started ART during anti-TB regime, in 
comparison with those who initiated ART only upon  completion of the anti-TB therapy.  
 
Disadvantage Comments
High pill burden More than 10 pills daily; discourage treatment adherence. 
Overlapping of adverse 
effects 
Hepatotoxicity promoted by H, R and Z and also by PI and NNRTI; 
increased risk of hepatitis C virus infection (Velasco et al., 2009). 
Gastrointestinal upset and rash are common in both therapies 
Peripheral neuropathy promoted by H, didanosine and stavudine 
Immune reconstitution 
inflammatory  syndrome 
(IRIS) 
Although  ART triggers the regeneration of  immune cells,  
the immune system unexpectedly produces an overwhelming 
inflammatory response that unmasks or worsens the co-
infection symptoms  (TB is  the most common among them);  
The risk of IRIS is the main ground to initiate  TB treatment 
prior to  ART, whenever it is possible. 
Its frequent symptoms  comprise fever, swollen lymphonodes, skin 
lesions and rashes, changes in breathing, pneumonia, hepatitis, 
abscesses and eye inflammation. They often appear within 2–6 
weeks from the beginning of  HIV therapy (Antonelli et al., 2010).  
Drug-drug interactions See Table 3
Table 2. Disadvantages from the  concomitant treatment of TB and HIV. 
Following these conclusions, another study performed by Blanc and collaborators provided 
strong evidences for an early start of ART administration (Blanc et al., 2010). The Cambodian 
Early versus Late Introduction of Antiretrovirals (CAMELIA) was an open label, prospective, 
randomized controlled trial, registering HIV-positive patients with a CD4 count <200/mm3 
and smear-positive TB living in Cambodia. This study demonstrated that the group treated 
with   ART within  2 weeks from the beginning of the  TB therapy showed a relevant  decline 
of 34% at the mortality rate, when compared with patients who received  ART only 8 weeks 
after the initiation of TB treatment. In  both studies, an increased incidence of IRIS was 
observed in patients who were  early treated with  ART. Nevertheless,  the data shown by the 
SPIT trial, namely a lack of mortality or changes in antiretroviral regime attributable to IRIS,  
also   corroborate the early ART initiation in HIV infection-related TB patients. 
2.4 Management of drug-drug interactions between antiretroviral and anti-TB agents 
The most delicate kind of  interactions  involves the concomitant use of  rifamycins (among 
which the most  usual are rifampicin and rifabutin),  NNRTIs and  PIs,  given that these last 
two classes of antiretroviral drugs are essentially metabolized through cytochrome P450 
(CYP) 3A4 enzymes, whose  expression is induced by rifamycins. Consequently, the plasma 
concentration and exposure of NNRTIs and PIs are significantly reduced, when they are 
concomitantly administrated with rifamycins (Burman et al., 2001). Furthermore, rifampicin 
improves the activity of the efflux multidrug transporter P-glicoprotein, which promotes the 
elimination of  PIs (Kim et al., 1998; Schuetz et al., 1996). Due to the reduction of NNRTIs 
and PIs  at the plasma concentration, as a result from the simultaneous administration of 
rifamycins,  the HIV treatment can fail, thus giving rise to the emergence of drug resistance. 
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The Table 3 below summarizes the most relevant interactions between  rifamycins and 
antiretroviral agents (Centers for Disease Control and Prevention [CDC], 2007). 
 
Antiretroviral 
agent 
Effects on pharmacokinetics parameters and comments
Rifampicin Rifabutin
NNRTIs 
EFV EFV AUC↓ by 22% 
Rifabutin AUC↓ by 38%
Increase Rifabutin dose to 450-600mg 
(daily or intermittent)
NVP NVP AUC↓ 37-58% and Cmin↓ 68% with 200mg 2x/day dose
NVP and Rifabutin AUC are not 
significantly changed
DLV 
DLV AUC↓ 95% 
Simultaneous use of such drugs 
should be avoided. 
DLV AUC↓ 95%
Rifabutin AUC↑100% 
Simultaneous use of such drugs should 
be avoided. 
PIs 
Ritonavir 
Ritonavir AUC*↓ by 35%
Monitor for antiretroviral activity 
of ritonavir
 
Fos-Amprenavir Simultaneous use of such drugs 
should be avoided.
Rifabutin dose ↓ to 150mg/day or 300mg 
3x/week
Atazanavir 
Atazanavir AUC↓ by >95%
Simultaneous use of such drugs 
should be avoided.
Rifabutin AUC ↑ by 250%
Rifabutin dose ↓ to 150mg every other 
day or  3x/week
Indinavir 
Indinavir AUC↓ by 89%
Simultaneous use of such drugs 
should be avoided. 
Rifabutin AUC ↑ by 34%
Rifabutin dose ↓ to 150mg/day or 300mg 
3x/week
Nelfinavir 
Nelfinavir AUC↓ by 82%
Simultaneous use of such drugs 
should be avoided. 
Rifabutin AUC ↑ by 207% 
Rifabutin dose ↓ to 150mg/day or 300mg 
3x/week 
Saquinavir 
Saquinavir AUC↓ by 84%
Simultaneous use of such drugs 
should be avoided. 
 
Saquinavir + 
Ritonavir 
Caution. The use of this 
combination could cause 
hepatitis.
 
Lopinavir + 
Ritonavir 
Caution. The use of this 
combination could cause 
hepatitis. 
Rifabutin AUC ↑ by 303%
Rifabutin dose ↓ to 150mg every other 
day or  3x/week
Fusion Inhibitors
Enfuvritide No interaction. No dose adjustment. No interaction. No dose adjustment. 
CCR5 receptor antagonists
Maraviroc 
Maraviroc Cmin↓ by 78%
Increase Maraviroc to 600mg 
twice-daily
Change Maraviroc dose to 300mg twice 
daily and rifabutin to 300mg daily 
Integrase 
Inhibitors 
  
Raltegravir Raltegravir concentratios ↓ by 40-61% 
Rifabutin trough ↓ by  20% Raltegravir 
AUC is not affected 
Change Rifabutin dose to 300mg daily 
and Raltegravir to 400mg twice daily 
*AUC= area under the plasma concentration time curve; estimated  bioavailability.  
Table 3. Management of interactions among anti-TB and anti-HIV drugs. 
www.intechopen.com
  
Global View of HIV Infection 
 
132 
3. Thiourea derivatives: A promising class against HIV/TB co-infection  
Due to such a number of  complications that may possibly arise in the course of  treatment 
of HIV-related TB, as described above,  the development of  new drugs against HIV and TB 
should be mandatory. Said medications  should  produce relevant effects, such as the 
improvement of patient well-being   by means  of the reduction of pill burden, as well as by  
the careful management of the overlapping toxicity  resulting from the treatment of TB and 
HIV infections. Therefore, an  alternative could be  the development of drugs that might be 
able to simultaneously act  in the treatment of both diseases. In this context, thiourea 
derivatives appear as a promising class of compounds. For instance, the 
tetrahydroimidazobenzodiazepinthiones (TIBO) derivative 9-Cl-TIBO and the 
phenylethylthiazolylthiourea (PETT) derivatives LY73497 and trovirdine (TRV) play a 
significant role in the inhibition of  HIV reverse transcriptase (Fig. 1). On the other hand, the 
compound isoxyl (ISO, thiocarlide), another thiourea derivative,  is known by its  strong 
anti-TB activity (Fig. 1). By the way, although used as part of  the TB  clinical treatment since 
the 1960’s, it may be pointed out that the relevance of ISO emerged from recent researches, 
and particularly from studies in the field of  new treatments against MDR-TB. Therefore, the 
main purpose  of this chapter is to highlight the importance of thioureas  for the TB-HIV 
drug discovery, and to proceed with a review of data from recent literature, by focusing  the 
most relevant contributions to  the development of new prototypes containing this 
promising scaffold. 
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Fig. 1. Active thioureas against HIV (9-Cl TIBO, LY73497 and trovirdine) or M. tuberculosis 
(ISO). 
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3.1 Thiourea derivatives showing a potential activity against HIV 
3.1.1 TIBO derivatives  
TIBO and HEPT [1-(2-hydroxyethoxymethyl)-6-(phenylthio)thymine] derivatives, yet 
discovered independently from each other, can be  reputed a landmark in the history of the 
antiretroviral therapy. These compounds were the first congeners from a new category of 
anti-HIV drugs, currently known as NNRTIs (De Clercq, 2004). At the beginning of the 
1990s, the only  drug that had been approved for AIDS treatment was  AZT, so that   
patients had  to live at imminent risk to develop resistant mutant virus. Therefore, it 
becomes quite clear that  the identification of a different class of antiretroviral drugs brought 
new perspectives in the  treatment of AIDS. 
The development of TIBO derivatives started from a screening program from the library of 
Janssen Research Foundation, working with 600 compounds  that were selected  due to  
their failure in producing effects on  the standard pharmacological assays, and to  their low 
toxicity in rodents as well (De Clercq, 2004). Upon evaluation of the  biological activity of 
these compounds against HIV-1/HTLVIIIB in MT-4 cells,   researchers identified the 
tetrahydro-benzodiazepine derivative R14458 (Fig. 2), which presented  a moderate anti-
HIV-1 activity (IC50= 62µM) (Pauwels et al., 1990). Using this substance as a lead compound, 
they  started a program aiming  at the improvement of its anti-HIV properties. Thereafter, 
several analogues were synthesized, thus allowing the  performance of an extensive 
structure-activity relationship (SAR) study of this class of compounds.   
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Fig. 2. Structure of TIBO derivatives R4458 and R78305.  
3.1.1.1 SAR of TIBO derivatives 
Considering that the compound R14458 is a racemic mixture, the authors initially 
investigated the role of  stereochemistry  in the biological activity of this substance. 
Although the  two optical isomers were synthesized and tested against HIV-1,  only the 
enantiomer R78305 (Fig. 2) with S configuration was found to be active, showing that this 
configuration is required for the anti-HIV-1 properties of TIBOs (Pauwels et al., 1990). The 
subsequent studies aimed  at the evaluation of systematic alterations in the structure of the 
lead compound, and its scaffold was independently modified in four different portions: the 
substituent bonded to the 6-positon nitrogen of the diazepine ring (Kukla et al., 1991a), the 
5-ring urea portion (Kukla et., 1991b), the 7-membered ring portion (Breslin et al., 1995) and 
the substituent of the aromatic ring (Ho et al., 1995). The results obtained in these studies are 
described in the next sections. 
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3.1.1.1.1 Modifications in the substituent bonded to the 6-position nitrogen of the diazepine ring 
Initially, it was verified that the presence of bulky groups attached  to this position  was 
mandatory to trigger anti-HIV-1 activity, since compounds containing hydrogen, ethyl or a 
linear propargyl substituent were inactive. The strongest activities were  observed whenever 
an unsaturated allyl group was attached  to the 6-positon nitrogen, such as in the lead 
compound, and it was verified that the substitution at the 2-position of this group led to 
more active compounds. The improvement degree of said  activity varied in accordance 
with the following sequence: ethyl > methyl = vinyl = bromo > H. On the other hand, all 
compounds containing 2-propyl, phenyl, benzyl or fused cyclohexenyl were inactive. 
Substitutions at the 3-positon of the allyl group were also verified, and the dimethyl 
substituted compound showed the highest degree of activity found in these series. 
Introduction of bulky groups at this position usually led to completely inactive compounds. 
In view of the above results,  an optimum size to  the substituent for both 2- and 3-positions 
is required, since the substance loses its activity, as  the length of  the side chain increases or 
decreases. Moreover, the groups attached to the nitrogen which led to inactive compounds 
were the following: acetylene, alkyl groups containing heteroatom, and methylene attached 
to functional groups such as, nitrile, ketone, ester, alcohol, ether or a heteroaromatic pyrrole 
or imidazole (Kukla et al., 1991a).  
3.1.1.1.2 Modification in the 5-ring urea portion 
This portion of the tricyclic TIBO structures underwent several modifications, among which 
we can mention  the replacement of  carbonyl carbon by: nitrogen, sulfur dioxide or deletion 
of the carbonyl oxygen yielding, that are, respectively, a triazine, a sulfonamide and an 
imidazole. However, in  the most part of trials, these modifications  gave rise to inactive 
compounds. The most promising result was found  by the replacement of the urea group by 
a thiourea, yielding a compound around one hundred times more active than the original 
prototype. The ring expansion, by  insertion of a methylene or another carbonyl, led to a loss 
of  anti-HIV-1 activity, and it was also verified that methylation of 1-positon nitrogen also 
gave rise to an inactive compound, probably in view of the need of  NH to form  hydrogen 
bonding (Kukla et., 1991b). 
3.1.1.1.3 Modifications at the 7-membered ring portion 
The demethylation of carbon in 5-position or introduction of bulky groups at this position 
yielded inactive or less active compounds, thus demonstrating that the size of the methyl 
group is optimum for the biological activity. The C-4 position showed a greater tolerance for 
larger groups, and the analogues  presented a good anti-HIV-1 activity. The  7-position also 
underwent replacements, whereby high levels of activity were once more achieved.  
However, among  the modifications performed at  the 7-membered ring, none of them led to 
the discovery of compounds  showing a better HIV inhibitory activity than the simplest 5-
mono-methyl-substituted analogue (Breslin et al., 1995). 
3.1.1.1.4 Evaluation of substituent effect on the aromatic ring  
In order to evaluate the substituent effect on the aromatic ring,  researchers  used both urea 
and thiourea derivatives, and maintained the optimal conditions described by previous 
works, such as the attachment of a methyl group  to the 5-position, and bonding of a 
dimethylallyl group  to  nitrogen at the 6-positon ( except  in case of compounds presenting  
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synthetic problems, where scientists had to use  a cyclopropylmethyl, also able to lead to 
high levels of activity). The best results were found for 8-substituted analogues, which, in 
comparison to the lead compound, showed  much higher potency,  so that  halogens 
reached the highest level of activities in the substituent group.   Iodine was the only 
exception to the above conclusions, probably due to its larger volume.  Compounds 
containing a methoxy or an acetylene group bounded at 8-positon displayed similar 
activities, when compared to the parent unsubstituted compound. Although the substitution 
of 8-methoxy group by 8-thiomethyl may have led to an improvement in the biological 
activity, the replacement of methoxy  by the  ethoxy group, which is larger, resulted in a 
decrease in  anti-HIV activity. Amino, aminoacetyl, dimethylamino and nitro analogues 
remained inactive. Furthermore, the substitutions at 9-positon led to the formation of 
compounds, whose  activities are similar to those of  the parent unsubstituted compound, 
while 10-substituted compounds  were found to be less active. The replacement of the 
aromatic ring by a heteroaromatic ring was also evaluated, but the derivatives were inactive 
(Ho et al., 1995). 
3.1.1.1.5 Clinical trial with 9-Cl-TIBO (R82913) 
Extensive  SAR studies with TIBO derivatives allowed the identification of substances with 
similar or better activities than other known antiretroviral drugs, such as AZT, 
dideoxycytidine (ddC) and Dideoxyinosine (ddI). Among these substances, thiourea  
9-Cl TIBO (R82913) (Fig. 1) was selected for a phase I clinical trial. This study evaluated 22 
patients, within the age group between 27-59 years old,  who showed   HIV infection in an 
advanced stage (Pialoux et al., 1991). The drug was administrated by daily intravenous 
injection through a peripheral or a central venous catheter. R82913 had to be injected in a 
dose  of 120-200mg, in order to   reach  the  concentration observed in vitro (20-40ng/mL), 
which is required for the protection against  HIV cytopathic effects. The measured half-life 
was of 3 days, and the pharmacokinetic profile of the substance was neither influenced by 
an increase of the dose, nor by its long-term administration.  In spite of its  side effects, 
which usually comprised phlebitis, drowsiness and fatigue, a general absence  of toxicity 
could be attributed to R82913. 
3.1.2 PETT derivatives 
3.1.2.1 Discovery of PETT series and preliminary SAR studies 
Phenethylthiazolylthiourea (PETT) analogues  integrate the powerful class of NNRTIs, 
first described by researchers from Lilly laboratories in the second half of the 1990’s 
(Ahgren et al., 1995). These compounds were discovered in an attempt to indentify the 
minimal structural elements that might be necessary for the development  of the thiourea 
derivative 9-Cl TIBO biological activity (Fig. 1). The researchers disconnected some bonds 
from the rigid tricyclic nucleus of this substance, thus producing simpler structures. The 
potential pharmacophores produced after the systematically disconnections were used to  
search  similar structures in the organic compound database of Lilly Research 
Laboratories. The study disclosed approximately  250 substances, whose activity against 
HIV was duly evaluated. The N-(2-phenethyl)-N’-(2-thiazolyl)thiourea, LY73497 (Fig. 3), 
was identified as the lead compound, and used in subsequent SAR studies (Bell et al., 
1995).  
SAR studies were performed by dividing LY73497 into four portions and proceeding with 
an aleatory variation of each  of them (Fig. 3) (Bell et al., 1995). Initially, the authors 
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modified the quadrant 1  of phenyl ring, introducing different substituents,  or replacing  
it by other aromatic heterocycles. They observed that meta and ortho substitutions 
generally triggers  better activities, when compared with the para one. As regards the 
electronic nature of ortho substituents, both small electron-donating and small electron-
withdrawing groups presented good activities, and, among said elements, the preferred 
groups are the following: fluoro, chloro, azido and methoxy. A combination of alkoxy and 
halogen substitution resulted in compounds with improved activity. Although the  
introduction of an ethoxy group in meta position may have led  to a good activity, the use 
of bulky alkoxy groups, such as propoxy and isopropoxy, seems to have been responsible 
for a reduction in the  activities. Among the substances containing a heterocycle  in 
replacement of the phenyl ring, the best activity was observed for the 2-pyridyl 
compound. Changes at  the nitrogen atom for the 3- and 4-position induced a decrease in 
the activity.  
                                                        
N
H
N
H
S S
N
LY73497
1 2 3 4
 
Fig. 3. SAR studies with PETTs derivatives.  
The modifications in quadrant 2 were characterized by changes in the length of the alkyl 
linker. The main conclusion was the identification of  an ethyl linker  as optimal  to the 
activities. It was also noted that the introduction of a methyl group in the benzylic position 
of  ethylene linker enhanced the activity, while  a methyl group in the phenethyl position 
led to its reduction. 
The variations in quadrant 3 demonstrated  the crucial role played by  thiourea moiety at  
the anti-HIV activity of these compounds. In fact, the replacement of  thiourea by  urea 
resulted in an inactive compound and other isosters, such as  cyanoguanidine derivatives,  
which appeared to be less potent. The methyl substitution  at the nitrogen adjacent to the 
thiazole ring leads to a less active compound, while  methyl substitution on the nitrogen 
adjacent to the phenethyl side chain provided  compound with no activity at all. This result 
is attributed to presence of an internal hydrogen bond between the hydrogen bonded to 
nitrogen adjacent to the phenethyl side chain and the nitrogen of the thiazole nucleus in 
LY73497. 
As regards  quadrant 4, it was observed that a heterocycle in this position is  determinant to 
reach a good activity. In general, substituted thiazoles were highly active, excepting  the 4-
carboxythiazolyl compound, whose lack of activity indicated  that the allosteric site of the 
enzyme does not accept a polar group. When  thiazole nucleus was replaced by another 
heterocyle, the 2-pyridyl analog  showed the highest level of activity.  
During a second phase of  SAR studies, the authors combined the optimal substituents in 
quadrants 1-4, and  observed that these parameters are additive, able to give rise to 
compounds with optimal activity. Among them, the compound LY300046, currently known 
as trovirdine (TRV; Fig. 1), was selected for further pharmacological examinations, since the 
hydrochloride salt of this compound showed acceptable blood levels, when orally 
administrated  in rats (Ahgren et al., 1995).   
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TRV displayed a comparable or a better ED50 than other known antiretroviral drugs, such as 
9-Cl TIBO, L697661, NVP, AZT, ddI and ddC, being capable of inhibiting the replication of 
HIV-1 in MT-4 cell culture, as well as  the replication of various clinical HIV-1 isolates  in 
MT-2 cells and PBL human cells. However, this substance showed no action  against HIV-2. 
When it was tested against resistant isolates containing mutations in Ile-100, Cys-181, and 
Ile-100–H-188 reverse transcriptase (RT), the trials disclosed a cross resistance  between 
trovirdine and other non-nucleoside compounds. Nevertheless, within the group of said  
non-nucleoside derivatives, trovirdine was found to present the highest level of  activity 
against these mutants. 
In the enzymatic assay with wild-type and mutant RT enzymes, TRV was  also more active 
than the non-nucleosides 9-Cl TIBO, L697661 and nevirapine, showing a lower IC50. 
After TRV  oral administration in rats (20mg/kg), a peak concentration in plasma of 3.5µg/mL 
was observed at 0.5h. The overall half-life was of 1 h, and the area under the concentration-
time curve was 6.9µg/h/mL. The peak concentration in brain was 2.9µg/g, and the area under 
the concentration-time curve was 5.9µg/h/mL. This result shows that TRV crosses the blood-
brain barrier, which is a desirable property of anti-retroviral agents, due to the risk of HIV-
associated encephalopathy in contaminated patients (Ahgren et al., 1995).  
Despite the promising  outcomes related to the use of TRV as NNRTI, the clinical trials 
focused on this compound   were suspended. Anyway, this substance is still considered a 
standard lead compound for the development of new PETT analogues, as it  encouraged the  
course of an extensive serie of SAR studies based on modern approaches, such as 
crystallographic techniques and molecular modeling. These works will be discussed in the 
next section. 
3.1.2.2 Rational design of new PETT analogues  
This study was initiated when Vig and  collaborators (Vig et al., 1998) proposed to synthesize  
series of novel PETT derivatives based on the structure of the non-nucleoside inhibitor (NNI) 
binding pocket of HIV-1 reverse transcriptase (RT). This composite binding pocket was built by 
superimposing nine individual crystal structures of RT-NNI complexes (Sudbeck et al., 1998). 
After having conducted docking studies with TRV, they  verified the existence of  multiple 
sites, which can be used for incorporation of larger functional groups, mainly surrounding the 
pyridyl ring, the ethyl linker and near the 5-bromo position. Hence, they proposed that a better 
use of these spaces by strategically designed functional groups could lead to a high-affinity 
binding and to the discovery of more potent anti-HIV agents.   In view of the above, they 
decided to study the effects of  introduction of several substituents in different positions of the 
phenyl ring, such as methoxy group, fluorine atom or chlorine atom (Table 4).  
These results disclosed by a preliminary SAR study  attest to the potency of PETT 
derivatives  phenyl ring substitutions on various positions  (Fig. 4). After analyzing the  
composite NNI binding pocket, the authors identified three promising PETT derivatives 
with ortho-F (HI-240), ortho-Cl (HI-253) and metha-F (HI-241) substituents on the phenyl 
ring, which showed potent anti-HIV activity (IC50 [p24] values of < 1nM), selectivity indexes  
(SI) of > 100,000, and were recognized to be  more active than AZT or TRV. Among them, 
HI-240 has been chosen as the lead compound, as it presented  the  highest level of activity 
against wide-type HIV RT. This finding could be  grounded on the examination of a 
composite binding pocket model, showing that  Wing 2 region is predominantly 
hydrophobic, except at the area nearby  ortho positions on both sides of the phenyl ring, 
which would be compatible with  polar groups, such as, for instance, halogen atoms.  
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N
HN N
H
S
Br
X
 
 
Compound X IC50 rRT (µM)a IC50 p24 (µM)b SIc 
HI-237 o-OMe 1.0 0.01 >1 x 104 
HI-240 o-F 0.6 <0.001 >1 x 105 
HI-253 o-Cl 0.7 <0.001 >1 x 105 
HI-239 m-OMe 0.4 0.003 >3 x 104 
HI-241 m-F 0.7 <0.001 >1 x 105 
HI-254 m-Cl 3.1 N.D. N.D. 
1 p-OMe 0.9 0.015 >6 x 103 
HI-242 p-F 6.4 N.D. N.D. 
HI-255 p-Cl 2.5 N.D. N.D. 
TRV ---- 0.8 0.007 >1 x 104 
AZT ---- >100 0.004 7 x 103 
a Purified recombinant HIV RT assay. 
b IC50 p24 values represent the inhibition of HIV-1 replication in relation to the virus control, as 
measured by p24 EIA. 
c SI (selectivity index) = IC50[MTA]/ IC50[p24]. IC50[MTA] values were >100µM. 
Table 4. IC50 and SI values for  series of PETT derivatives. 
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Fig. 4. Preliminary SAR of PETT derivatives. 
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The authors postulated that the lead compound HI-240 would be effective against HIV RT 
mutants (Mao et al., 1999). This hypothesis was confirmed, since HI-240 is three times more 
potent than TRV against the multiple-drug-resistant of HIV RT, thus  emphasizing the  
relevance of a polar ring substituent,  which could provide more favorable interactions with 
binding site residues (Table 5).  
During this SAR study, Mao and  collaborators (Mao et al., 1999) rationally designed a novel 
PETT analogue (HI-236), by using the computer model of NNI binding pocket. This 
derivative was designed through the optimization of van der Waals contact with the 
binding pocket, mainly at Wing 2 region, that  presents unrecognized spacious regions 
surrounding the phenyl ring. This strategy would improve the potency against wild-type 
RT, and also against Wing 2 mutants of RT.  In view of the above, the authors proposed the 
synthesis of HI-236,  whose 2,5-dimethoxy-substituted phenyl ring   allows favorable 
contacts with Wing 2 region, and also decreases the unoccupied volume surrounding 
phenyl ring of HI-240 by 25 Å3. Therefore, HI-236 showed a potent anti-HIV activity (IC50 < 
0.001µM), which is lower than IC50 values for AZT (0.004 µM). This substance was not 
cytotoxic, and its calculated selectivity index was > 105.  
Furthermore, HI-236  was found to be highly effective against  multidrug-resistant HIV-1 strain 
RT-MDR, whose  multiple mutations involve several RT residues (Table 5). These results are 
consistent with the prediction  according to which HI-236 would be more active than HI-240. 
 
Compounds IC50 p24 IC50 RT-MDRa IC50 A17b IC50 A17 variantb 
HI-236 <0.001 0.005 0.1 11 
HI-240 <0.001 0.005 0.2 41 
DLV 0.009 0.4 50 >100 
NVP 0.034 5 >100 >100 
TRV 0.007 0.02 N.D. N.D. 
AZT 0.004 0.15 0.006 0.004 
a V106A mutation 
b Genotypic NNRTI-resistant HIV-strains (A17 and A17 variant) carrying clinically relevant mutations 
Y181C and K103N + Y181C, respectively. 
Table 5. Inhibitory activity of HI-236 and HI-240 on p24 production in peripheral blood 
mononuclear cells infected with HIV strains HIVIIIB, RT-MDR, A17 and A17 variant. 
In another work, Mao and  collaborators (Mao et al, 1998)  proposed the synthesis of new 
PETT analogues through  replacement of the planar pyridyl ring of TVR  by a non-planar 
ring, such as a piperidinyl (HI-172) or piperazinyl ring (HI-258). This modification was 
based on the presence of unrecognized spacious regions surrounding the pyridyl ring of 
TRV (molecular volume (MV)= 160Å3), which could be better filled than the spacious Wing 
2 region of the butterfly-shaped NNI binding pocket. In comparison with the MV of TRV,  
HI-172 and HI-258 presented larger MVs  (calculated in 276 and 272Å3 respectively), being 
thus  predicted to better fit into the potentially usable space of the binding site. 
Furthermore, these heterocyclic rings are conformationally more flexible than the pyridyl ring, 
such a factor being likely  to contribute to fit an uncompromising binding pocket  in a more 
efficient way. Table 6 shows that both compounds were more potent than TRV, and that they 
inhibited HIV replication at nanomolar concentrations, without showing  cytotoxicity. These 
findings indicate that, when compared to TRV analogues, double substitutions at axial or 
equatorial positions on these heterocyclic rings could lead to PETT derivatives with a broader 
range of curvatures, and that they would also better fit to Wing 2 region. 
www.intechopen.com
  
Global View of HIV Infection 
 
140 
Compound IC50 p24 IC50 [MTA]* SI 
HI-172 <0.001 >100 >1 x 105 
HI-258 0.002 >100 >5 x 104 
TRV 0.007 >100 >1 x 104 
AZT 0.006 50 8 x 103 
* MTA= Methyl tetrazolium assay  
Table 6. IC50 and SI values for  series of PETT derivatives. 
Following  their continuous program  aiming at the development of new potent PETTs, 
Uckun and  collaborators (Uckun et al., 1999a)  decided to replace the pyridyl ring of TRV  
by an aciclyc cyclohexenyl, adamantly or cis-myrtanyl ring. Such a proposal of  
modifications was due to the fact that these chosen groups would fit well with Wing 2 
region of the NNI binding pocket.   Given the existence of a region compatible with polar 
atoms at Wing 1, the authors  also  suggested the replacement of bromine atom by chlorine 
or trifluoromethyl group (Table 7). After a biological evaluation, they  observed that the 
replacement of the pyridyl ring of TRV by the adamantly (HI-504) or cis-myrtanyl (HI-444) 
rings resulted in a complete loss of RT inhibitory function. In another  important finding,  
bromine (HI-346) / chlorine (HI-445) atoms were found to reach the best biological result, 
thanks to their capacity of making  more hydrophobic contacts at the binding pocket, when 
compared to trifluoromethyl group (HI-347). Moreover, the lead compounds HI-346 and 
HI-445 showed a significant activity against the multidrug resistant (MDR) strain, without 
presenting  cytotoxicity, when administrated at effective concentrations (Table 7). 
 
 
 
Compound Ring X 
CC50 
MTA 
(µM) 
IC50 (µM) 
p24 RT-MDR A17 
A17 
variant 
HI-346 Cyclo-hexenyl Br >100 0.003 0.020 N.D. 18.7 
HI-445 Cyclo-hexenyl Br >100 0.003 0.001 0.068 30 
HI-347 Cyclo-hexenyl Cl >100 0.079 0.038 0.300 >100 
HI-504 Adamantyl* CF3 N.D.a N.D.a N.D.a N.D.a N.D.a 
HI-444 Myrtanyl* Br N.D.a N.D.a N.D.a N.D.a N.D.a 
TRV Pyridyl Br >100 0.007 0.020 0.500 >100 
AZT ----- ---- >100 0.004 0.2 0.006 0.004 
* methylene group, instead of ethyl linker 
a N.D.= not determined, because IC50 rRT (µM) > 100 
Table 7. CC50 and IC50 values for  series of PETT derivatives. 
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Uckun and  collaborators (Uckun et al., 1999b) carried on performing their  PETT derivatives 
SAR study, and decided to promote new replacements of the pyridyl ring of TRV with eight 
different heterocyclic substituents, including heterocyclic amines, heteroaromatic rings 
furan and thiophene, as well as  aromatic acetal piperonyl. After evaluation of HIV-RT 
inhibitory activity, the authors  concluded that these proposed modifications were critical 
for the biological activity of said  series of compounds, as  only the thiophene-substituted 
derivative HI-443 inhibited recombinant RT in vitro in more than 90% (Table 8).  
 
N
HN N
H
Ring
S
Br  
 
Compound Ring IC50 rRT (µM) IC90 rRT (µM) 
HI-443 Thiophene 0.8 15.0 
HI-230 Pyrrolidine 4.9 >100 
HI-436 Imidazole >100 >100 
HI-442 Indole 0.9 >100 
HI-206 
1-methyl-
pyrrolidine >100 >100 
HI-276 Morpholine >100 >100 
HI-257 Piperonyl* 0.7 >100 
HI-503 Furan* 1.2 >100 
TRV Pyridine 0.6 12.0 
* Methylene linker group, instead of an ethyl linker. 
Table 8. RT inhibitory activity of PETT derivatives, expressed as IC50 and IC90 values. 
After proceeding with docking studies, it was observed that the thiophene group of HI-443 
occupies the same Wing 2 region of the NNI binding pocket of RT as TRV,  although with a 
smaller molecular volume. Moreover, the geometry of  hydrogen bond between 2´-NH atom 
and the amide carbonyl or TR residue 101 deviates from the optimum geometry that  
authors had observed in relation to TRV and other PETT derivatives, such as HI-172 (Table 
6).  Said remarks could justify the lower inhibitory activity of HI-443 against HTLVIIIB RT,  in 
comparison with TRV (Table 9). Surprisingly, when HI-443 was assayed against NNI-
resistant and MDR-HIV strains, it  showed  excellent results (Table 9).  This finding  is in 
perfect accordance with the docking analysis, as this latter revealed that  thiophene group is 
located very close to  the Y181 residue. Therefore, in the Y181C mutant strains, the sulfur 
atom from its thiophene group may be more compatible with the sulfur-containing cysteine 
181 residue than the pyridyl group of TRV. 
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Compound 
CC50 
MTA 
(µM) 
IC50 (µM) 
p24 RT-MDR A17 A17 variant 
HI-443 >100 0.030 0.004 0.048 3.3 
HI-172 >100 <0.001 >100 >100 >100 
HI-240 >100 <0.001 0.005 0.200 41 
TRV >100 0.007 0.020 0.500 >100 
AZT >100 0.004 0.2 0.006 0.004 
Table 9. Anti-HIV activity of PETT derivatives. 
In their next work, Venkatachalam and  collaborators (Venkatachalam et al., 2001)  
designed, synthesized and evaluated 13 aromatic/heterocyclic thiazolyl thiourea 
compounds, since thiazolyl group  was expected to favorably bind to Wing 1 region of the 
binding pocket of HIV-1 RT (Table 10).  
 
N
H
N
H
S
Ring n S
N
2-14  
 
Compound n Ring 
IC50 (µM) 
CC50 
(µM) 
SI 
HTLVIIIB A17 
A17 
variant 
2 Et 2-Thiophene <0.001 >100 N.D. 71 71,000 
3 Et 2-Cyclo-
hexenyl 
0.007 0.9 >100 4 571 
4 Et 1-phenoxy <0.001 4.4 >100 >100 >100,000 
5 Et 4-methyl-phenyl 0.07 3.9 >100 >100 1459 
6 Me 1-Adamantyl <0.001 0.6 1.3 40 40,000 
7 Pr 2-Furan <0.001 2.0 0.6 >100 >100,000 
8 Et 1-Imidazole <0.001 >100 >100 35 35,000 
9 Et 3-indole <0.001 2.2 3.7 28 28,000 
10 Et 1-pyperidine >100 N.D. N.D. N.D. N.D. 
11 Et 4-hydroxy-phenyl >100 N.D. N.D. N.D. N.D. 
12 Et 2-pyridine 1 N.D. N.D. 100 100 
13 Pr 1-pyrrolidinone 9 N.D. N.D. 18 2 
14 2-Bu Phenyl 0.009 2.1 1.5 10 1111 
NVP ---- ---- 0.034 >100 >100 N.D. N.D. 
DLV ---- ---- 0.009 50 >100 N.D. N.D. 
Table 10. Anti-HIV activity of thiazolyl thiourea derivatives. 
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Among 13 compounds, six lead  ones were detected (2, 4 and 6-9). They were 9-34 times 
more active than the standard NNRTI nevirapine and delavirdine. The compounds 2-9 and 
14 were also tested against NNRTI-resistant strains A17 with Y181C mutation and A17 
variant with a Y181C plus K103N mutations in RT. The most promising compounds were 6, 
7, 9 and 14, as they were effective against both NNRTI-resistant HIV-1 isolates and showed 
much greater potency against both wild-type and  NNRTI-resistant HIV-1 than nevirapine 
and delavirdine. Among these compounds, the most promising was the 7, due to its  
minimal cytotoxic effects on PBMC, as well as to its  selectivity index  > 100,000. 
 Subsequently, Venkatachalam and  collaborators (Venkatachalam et al., 2000)  proposed to 
study the influence of  stereochemistry of Halopyridyl and Thiazolidyl thiourea compounds  
on their potency as NNRTI.  For this purpose,  they  synthesized and measured  anti-HIV 
activity of  R and S stereoisomers of two cyclohexyl methyl haloperidyl thiourea compounds 
(HI-509 and HI-510), of two ǂ-methyl benzylhalopyridyl thiourea compounds (HI-511 and 
HI-512) and of one cyclohexyl ethyl thiazolyl thiourea  compound (HI-513) (Table 11).  
 
N
X
HN N
H
S CH3
N
X
HN N
H
S CH3
HN N
H
S CH3
N S
HI-513X=Br; HI-511
X=Cl. HI-512
X=Br; HI-509
X=Cl. HI-510
X=H; HI-542 (S)
          HI-543 (R)  
 
Compound 
IC50 (µM) 
rRT HTLVIIIB RT-MDR A17 
A17 
variant 
HI-509(R) 1.2 0.001 0.2 0.4 10.0 
HI-509(S) >100 >1 N.D. N.D. N.D. 
HI-510(R) 1.4 0.025 0.06 0.07 8.2 
HI-510(S) >100 >1 N.D. N.D. N.D. 
HI-511(R) 1.6 0.01 0.005 0.01 2.7 
HI-511(S) >100 >1 N.D. N.D. N.D. 
HI-512(R) 1.2 0.010 0.010 0.2 10.2 
HI-512(S) >100 >1 N.D. N.D. N.D. 
HI-513(R) 13.0 0.001 5.6 0.9 5.8 
HI-513 (S) >100 >1 N.D. N.D. N.D. 
HI-542 (S) >100 >1 N.D. N.D. N.D. 
HI-543 (R) >100 >1 N.D. N.D. N.D. 
TRV 0.8 0.007 0.02 0.5 >100 
Table 11. Effects of stereochemistry on anti-HIV activity of thiourea compounds. 
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The results  showed that  R stereoisomers of all five compounds inhibited the recombinant 
RT in vitro with IC50 values that were 100-fold lower. Each one of these five compounds was 
also active against NNI-resistant HIV-1 strains. Among them, HI-511(R) (see Table 11)  
presented a potent antiviral activity against NNI-resistant and multidrug resistant strains of 
HIV-1. 
Molecular modeling studies indicated that the R steroisomer [HI-509(R)] would fit the target 
NNI binding pocket on HIV-RT much better than its enantiomer [HI-509(S)]. Due to the 
presence of unfavorable steric interactions with the NNI binding pocket residues near the 
Y181 side chain, HI-509(S) adopts an energetically unfavorable eclipsed conformation, 
which reflects in its higher IC50 value. These assumptions could  also  apply in favor of HI-
510(R). As a relevant data concerning  this study, it is worthy to mention that the methyl 
group on  chiral carbon of HI-509(R) and HI-510(R) probably promotes the strong binding 
to the NNI binding pocket via van der Waals with residue V179. 
The substitution of the pyridyl ring of HI-509(R)  and HI-510(R) by a thiazolyl ring 
(compound HI-513(R)) resulted in 10-fold higher IC50 values in cell free RT inhibition 
assays, as the unsubstituted thiazole could be better accommodated by the binding site than 
the unsubstituted pyridine (in combination with the bulky cyclohexylethyl group) as a 
whole molecule. Nevertheless, halogen substitution on pyridine adds a considerable 
number of favorable interactions at Wing 1 region, which improves the final interaction 
score for the substituted pyridine thiourea compounds. 
While studying the effect of stereochemistry on  anti-HIV activity of chiral thiourea 
compounds, Venkatachalam and  collaborators (Venkatachalam et al., 2004)  synthesized 
two new series of PETT compounds: ǃ-methyl phenylethyl thiourea (ǃ-MPT), and ǂ-methyl 
benzyl thioureas  (ǂ-MBT) (Fig. 5).  
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Fig. 5. ǃ-MPT and ǂ-MBT series. 
These derivatives were evaluated against HIV-1 strain HTLVIIIB , and also against NNRTI-
resistant strains. Upon analysis of  these results, the authors  expressed critical positions  
regarding SAR of this class of compounds (Fig. 6).  
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Fig. 6. Complementary SAR study of chiral thiourea compounds. 
Among all synthesized compounds, the derivative 15 (Table 12), namely the R isomer 5-
chloropyridyl (ǃ-MPT Series), was 380-fold more active than nevirapine, 2-fold more active 
than trovirdine and 190-fold more potent against A17 than delavirdine. The compound 15 
was also  >200-fold more potent against A17V than nevirapine, trovirdine or delavirdine.  In 
view of these results, the authors  postulated that ǃ-MPT compounds may be useful 
candidates  to further development as anti-HIV agents, especially due to their  remarkable 
activity against mutant strains of HIV-1. 
 
H
N
H
N
S
CH3
N
Cl
15  
 
Compound 
IC50 (µM) 
rRT HTLVIIIB RT-MDR A17 
A17 
variant 
15 0.1 <0.001 0.02 0.3 0.5 
TRV 0.8 0.007 0.02 0.5 >100 
Table 12. Anti-HIV activity of thiourea derivative 15. 
Besides the modifications on the pyridyl ring, Sahlberg and collaborators (Sahlberg et al., 
1998) decided to investigate the replacement of thiourea by urea moiety in PETT derivatives. 
Furthermore, they have prepared compounds with an ethyl linker (Series I) and other 
conformationally restricted cyclopropyl analogues (Series II, Table 13).  
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N
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R3Series I Series II
16-21 22-28  
 
Compound R1 R2 R3 R4 
ED50 (µM)a
wt wtb T181C L100I 
16 H F F Cl 0.03 0.85 >32 32 
17 NMe2 F F Br 0.5 N.D. >25 >25 
18 OMe F OMe Cl 0.011 0.09 3 17 
19 OEt F OMe Cl 0.13 N.D. >27 14 
20 COMe F OMe Cl 0.2 N.D. >27 >27 
21 OEt Cl F Br 0.07 N.D. 8 15 
22 H F F Cl 0.006 0.01 N.D. N.D. 
23 OEt Cl F Cl 0.016 0.06 N.D. 0.1 
24 OEt Cl F CN 0.01 0.02 0.53 0.27 
25 OEt F F Cl 0.008 0.03 0.27 0.75 
26 OMe F OMe Cl 0.012 0.1 2.7 1.6 
27 OEt F Cl Cl 0.008 N.D. 0.1 0.1 
28 OEt F Br Br 0.025 0.8 N.D. N.D. 
TRV ---- ---- ---- ---- 0.02 5 >5 0.8 
a The cell culture assay used MT4 cells infected with HIV-1IIIB. 
b The assay contains 15% human AB serum. 
Table 13. Inhibition of HIV-1  by urea-PETT compounds. 
Cyclopropyl compounds  use to be more potent than the ethyl linked  ones, especially on 
mutants (Table 13). The authors hypothesized that, in comparison with the most restricted 
cyclopropyl analogues, the most flexible ethyl derivatives might  present inconvenient  in 
adopting conformations that fit in the mutant enzymes. 
When compared with thiourea analogues,  urea derivatives are less active (Fig. 7), although 
these compounds might have better toxicological and pharmacokinetic properties. In 
addition,  it was  verified later that, in cell culture and in the presence of added human 
serum, urea-PETT compounds keep their antiviral activity in standards that are much 
higher than those shown by the respective thiourea compounds. 
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Fig. 7. Anti-HIV activities of thiourea and urea derivatives.  
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Following this study, Högberg and collaborators (Högberg et al., 2000) have proposed 
several bioisosteric substitutions of  both thiourea and urea moieties of PETT compounds  
by sulfamide, cyanoguanidine and guanidine groups (Series III, Fig.8). Furthermore, they 
have promoted the replacement of the phenetyl group  by benzophenethyl group, in an 
attempt to  evaluate the influence of said modifications on the antiviral activities of this class 
of compounds (Series IV, Fig.8).  
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Fig. 8. Structures of two series of PETT analogues, obtained through bioisosteric modifications. 
The biological results showed that thiourea and urea moieties play an essential role  in the 
optimal activity of PETT compounds,  as all the proposed bioisosteric replacements  lead to a 
reduction (compounds with guanidine group) or to the complete loss of activity (sulfamide 
and cianoguanidine derivatives). Moreover, the benzoylethyl derivatives were reasonably 
potent inhibitors of wild-type HIV-1 RT and HIV-1 virus in cell culture. However, these 
derivatives were less active than the phenethyl compounds (see compound 39, Table 14). 
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Compound Ar Y X 
IC50 HIV-1 RT 
(µM)a 
ED50 (µM)b 
29 phenyl S Br <0.027 0.036 
30 2-F- phenyl S Br 0.004 0.009 
31 2-Cl- phenyl S Br 0.010 0.100 
32 2-OMe- phenyl S Br 0.003 0.076 
33 2-F- phenyl O Br 0.054 0.201 
34 3-OMe- phenyl S Br 0.080 0.911 
35 4-F- phenyl S Br 0.047 0.300 
36 2,5-F- phenyl S Br <0.025 0.067 
37 2,6-F- phenyl S Br 0.006 0.028 
38 2,6-F- phenyl S Cl 0.003 0.050 
39 2,6-F- phenyl* S Br 0.001 0.010 
a HIV-1 RT assay which used (poly)rC.(oligo)dG as the templae/primer.  
b Anti-HIV activity assay, using MT4 cells (human T cell line) infected with HIV-1IIIB 
*Phenylethyl, instead of benzoylethyl linker.  
Table 14. IC50 and ED50 values for Series IV. 
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3.1.2.3 PETT derivatives as anti-HIV microbicides 
D´Cruz and  collaborators  started to develop a vaginal microbicidal contraceptive, which 
was potentially  able to prevent HIV transmission. Thus, they  decided to evaluate two 
potent anti-HIV PETT derivatives (HI-240 and HI-236, Table 5), that had been previously 
identified by Venkatachalam and collaborators (Vig et al, 1998; Mao et al., 1998), in an 
attempt to verify a possible  dual-function, namely its anti-HIV and spermicidal activity. 
After proceeding with the analysis of  the results, they observed that only the derivative HI-
240 showed a spermicidal activity, although the underlying mechanism involved in such a 
function remains  unknown. Moreover, HI-240  inhibited the sperm motility, in a 
concentration-and time-dependent way (D´Cruz & Venkatachalam et al., 1999).  
Subsequently, the authors  investigated the cytotoxic characteristics and selectivity of this 
compound, and, then, compared their  results to nonoxynol-9 (N-9), which is the most widely 
used vaginal spermicide. This substance immobilizes sperm, as a result  from a detergent-type 
action on the sperm plasma membrane.  Due to its membrane-disruptive properties, a 
continued use of N-9 has been shown to be likely to damage the cervicovaginal epithelium, 
causing an acute tissue inflammatory response, and thus enhancing the probability of HIV 
infection by heterosexual transmission. When compared with N-9, HI-240 was selectively 
spermicidal, without  detergent-type  toxicity against membrane of the female genital tract, 
which may present significant clinical advantages. Another important feature of HI-240 may 
still be pointed out, namely the possibility for spermicidal NNI to remain stable as protonated 
species, even within  the acidic environment of the vagina, due to the presence of pyridine 
ring,  containing a basic nitrogen atom. Furthermore, the vaginal concentrations of this 
substance required for dual-action anti-HIV and spermicidal activity are well below the 
systemic concentrations achieved by the oral dosages that are generally prescribed for NNIs.  
In view  of these promising results, D´Cruz and  collaborators (D´Cruz et al., 2000)  decided to 
evaluate other 31 PETT derivatives for anti-HIV and sperm inhibitory activity (SIA) (Fig.9).  
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Fig. 9. Structures of thiourea derivatives, evaluated as spermicidal microbicides. 
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Among all these substances, they  identified several dual-function of thiourea compounds, 
such as the phenyl ring-containing derivatives HI-240 (2-fluoro), HI-253 (2-chloro) and HI-
255 (4-chloro) and the cyclohexenyl ring-containing derivatives HI-346 and HI-445, which 
were identified as potential lead compounds for the development of clinically useful dual-
function anti-HIV spermicides (Table 15). In this study, the authors also demonstrated that, 
at a spermicidal concentration, the dual-function thiourea derivatives were selectively 
spermicidal, without cytotoxic effects  against human vaginal, ectocervical and endocervical 
epithelial cells .  
 
Compound 
IC50 (µM) EC50 (µM) 
SIA p24 rRT 
HI-240 <0.001 0.60 147 ± 18 
HI-253 <0.001 0.70 70 ± 8 
HI-255 0.001 2.50 160 ± 16 
HI-346 0.003 0.6 42 ± 9 
HI-445 0.003 0.5 57 ± 5 
HI-142 (TRV) 0.007 0.8 >500 
Table 15. Effect of PETT derivatives on p24 antigen production in HIV-infected PBMC, as 
well as enzymatic activity of HIV-1 RT and human sperm mobility. 
Considering that the most promising dual-function microbicides PETTs were HI-346 and 
HI-445, which are cyclohexenyl ring-containing derivatives, D´Cruz and  collaborators  
decided to investigate other cyclohexenyl thiourea (CHET) compounds,  in order to examine 
the way how heterocyclic rings and their functionalization affect the  anti-HIV and SIA 
potency of these substances (D´Cruz et al., 2002a). Furthermore, some urea compounds were 
also evaluated, in an attempt to  determine the role of thiourea moiety in  the biological 
activity of these series (Table 16).  
In view of the data obtained, the authors  concluded that, among the thiazolyl-ring 
containing CHET compounds, only the 4-methyl-substituted derivative (42) showed a 
significant anti-HIV activity. As a matter of fact,  compounds containing benzothiazole-ring  
generally present poor anti-HIV activities. Among the compounds containing N-pyridyl 
nucleus, the functionalization at 5-position with bromine, chlorine and methyl groups led to 
a potent anti-HIV activity of CHET compounds. The thiourea moiety was essential  to 
trigger said anti-HIV activity, as its replacement by urea group either abolished (44) or 
reduced (45) the biological activity.  
Among 15 derivative compounds that were evaluated for  spermicidal potential,  12  
showed an improvement of spermicidal function, when analyzed at micromolar 
concentrations. The authors  observed that compounds with methyl group at 4- or 6-postion 
were non-spermicidal, even at concentrations >500µM. The pyridyl-ring containing CHET 
compounds with bromine or chlorine attached  to 5-position showed an excellent SIA 
activity, in addition to their remarkable anti-HIV activity. Interestingly, the urea 
compounds, although having retained SIA, presented a poor anti-HIV activity, . Another 
curious data arises from the comparison between  the values of T1/2 relating to thiourea and 
urea compounds, showing that  urea analogues immobilized sperm 38-fold faster than 
thiourea derivatives. 
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* Time required for 50% sperm mobility loss. 
Table 16. Anti-HIV and sperm immobilization activity of a serie of PETT derivatives. 
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Furthermore, the lead compounds HI-346 and HI-445 were evaluated in their activity 
against NNI-resistant strains (RT-MDR, A17 variant), and  were found to be more effective 
than TRV, delavirdine and nevirapine. These findings established the dual-function 
compounds HI-346 and HI-445 as potent NNI of drug-sensitive, as well as multidrug-
resistant strains of HIV-1. 
Due to the fact that the compound HI-346 is  a broad-spectrum anti-HIV agent with SIA, and 
also to the characteristic of  its urea analogue 44  as an extremely rapid spermicidal, the 
authors  decided to evaluate the in vivo fertilizing ability of sperm exposed to the lead dual-
function CHET compound HI-346, either alone or in combination with its structural analogue 
(compound 44), in the rabbit model. They  observed that the conception was completely 
inhibited after insemination with semen treated with compound 44, or HI-346 plus 44. 
 As to the cytotoxic profile, CHET-NNIs showed high selectivity indexes  against these 
genital tract epithelial cells in vitro. Moreover, in rabbits, the lead thiourea/urea compounds 
are not harmful to vaginal mucosa,   in spite of their  potent spermicidal properties,  when 
added either to human or to rabbit semen. 
These results indicated that the extremely rapid SIA of the urea analogue, as well as the 
broad-spectrum anti-HIV activity of spermicidal CHET-NNIs, together with their lack of 
mucosal toxicity and the remarkable ability to reduce in vivo fertility, appear as features that 
are particularly attractive to encourage the clinical development of a dual-function 
spermicidal microbicide (D´Cruz et al., 2002a). 
The next step performed by D´Cruz and  collaborators was the investigation on subchronic 
intravaginal toxicity of HI-346 in mice. Thus, HI-346 was formulated via lipophilic gel-
microemulsion for intravaginal use as a potential dual-function microbicide. In order to 
evaluate the potential toxicity of short-term intravaginal exposure to HI-346, groups of 15 
female B6C3F1 and CD-1 mice underwent an intravaginal exposure to a gel-microemulsion 
containing 0, 0.5, 1.0, or 2.0% HI-346, 5 days per week, for 13 consecutive weeks.  
Subsequently, the authors concluded that repetitive intravaginal administration of HI-346 to 
yield effective spermicidal and antiviral concentrations is not expected to  lead to local, 
systemic, or reproductive toxicity (D´Cruz et al., 2002b). 
In another study, D´Cruz and  collaborators decided to evaluate the PETT derivative HI-236 
as microbicide,  as, in accordance with a previous work, this compound  had already 
presented a broad-spectrum of anti-HIV activity (Mao et al., 1999).  In view of the above the 
authors demonstrated  that HI-236 showed a high-selectivity index against both human 
vaginal and cervical epithelial cells, without  affecting the human sperm functions. 
Furthermore, HI-236 was able to prevent the HIV systemic infection via  vaginal route. 
Therefore, HI-236 presented a  clinical utility as  non-spermicidal microbicide to curb the 
transmission of HIV via semen: (a) in sexually active women, to allow pregnancy, while 
protecting both mother and her fetus or infant from HIV-1 and (b) as a prophylactic antiviral 
agent for HIV-1 serodiscordant couples, or  for use before assisted reproductive technology 
procedures (D´Cruz & Uckun, 2005).  
3.2 Thiourea derivatives with potential activity against TB 
3.2.1 Isoxyl  
The thiocarbanilide Isoxyl (ISO, thiocarlide, 4,4’-diisoamythio-carbanilide) (Fig.1) was 
synthesized in 1953 by Buu-Hoi an Xuong. In this work, the authors described the 
antimicobacterial activity of several thioureas, among which some  are more active than 
ISO; however, this substance was chosen for subsequent assays, due to its better absorption, 
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and also to its  good tolerance even at the highest therapeutic doses (König, 1970). 
Pharmacological data demonstrated that,  upon this drug ingestion, the human serum 
presented fluctuating levels of ISO,  that exceeded its minimum inhibitory concentration 
(Tousek, 1970). Besides, given  its remarkable characteristics,  this substance has been used 
at the clinical treatment of  TB since the 1960’s. ISO was employed both: in monotherapy 
and in combined therapy, such as: ISO-isoniazid (I), ISO-streptomycin (S), ISO-I-S and ISO-
para-aminosalicylic acid (PAS). These studies reached good  results  (some of which are 
shown at  Table 17), especially in patients with pulmonary TB resistant to isoniazid, 
streptomycin and PAS, as well as in patients with hyper allergic reactions against others 
drugs or hepatitis as a result  from I (Tousek, 1970; Urbancik, 1970). However, when 
compared with other combinatory regimes, such as I-PAS and S-PAS, the results achieved 
with ISO appeared to be quite mediocre, thus culminating with  the introduction of more 
powerful antituberculosis drugs,  such as ethambutol, and with the consequent 
discontinuation of  ISO  administration. Nevertheless, in view of the worldwide 
dissemination  of MDR-TB and XDR-TB (World Health Organization, 2010a), a  re-
evaluation of drugs which were formerly deemed to be effective against TB  is a promising 
strategy for the development of new treatments, so that,  in this context, ISO  may be 
considered as  a strong candidate.   
 
Combination Months of therapy Negative on culture (%)a 
ISO (6 g) 1.5 – 4.5 47 
ISO – I (6 g/600 mg) 4 89 
ISO – I (6 g/10 mg/Kg) 6 75 
ISO – I (6 g/5 mg/Kg) 6 63 
ISO – S – I (4 g/1 g/200 mg) 6 83 
ISO – PAS (6 g/12 g) 6 50 
apercentage of patients  who had presented negative cultures.  
Table 17. Examples of results achieved in clinical trials with ISO (Tousek, 1970) 
In a recent report, Phetsuksiri and  collaborators (Phetsuksiri et al., 1999) evaluated the 
minimal inhibitory concentration (MIC) of ISO against various clinical isolates of 
susceptible and MDR-TB strains (Table 18). The growing of all tested strains was inhibited at 
low concentrations, with a MIC ranging  between 1-10µg/mL, which are  smaller than the 
maximum serum levels observed in humans for ISO (10-13.2µg/mL) (König, 1970). The 
authors also verified the effect of ISO on viable M. tuberculosis in vitro bone marrow 
macrophage assay, where this substance showed an ability to inhibit  bacterial growth 
inside the macrophage,  as well as a bactericidal activity, by reducing the initial inoculum of 
virulent M. tuberculosis. Another interesting result  from this assay  disclosed that ISO 
showed no acute level of  toxicity for mouse macrophages.   
 Together with the early studies performed with ISO in the 1960s, the recent results 
corroborate the capacity  of this substance to be used as an anti-TB drug, particularly in the 
development of new regimes to  MDR and XDR-TB treatment.  Such a characteristic is a 
direct result from ISO mechanism of action,  which  considerably differs from those 
presented by other  known anti-TB drugs. 
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Strain Designation Drug Resistance MIC (µg/mL) 
CSU 15 I 5.0 
CSU 21 I, R, E, S, Rfb 5.0 
CSU 22 I, R, E, S, Kan, Cap, AMK 10.0 
CSU 31 I, R, E 10.0 
CSU 32 I, R, E, Cyc, ETH, Z 10.0 
CSU 37 ----------------------------------------------------- 5.0 
CSU 39 I, R, S, Kan, AMK, ETH 10.0 
CSU 44 I, R, E, S, Kan, Z 10.0 
W 670 I, R, E, S, Kan 5.0 
W 3432 I, R, E, S, Kan, AMK, ETH, Cip 5.0 
BB ----------------------------------------------------- 1.0 
LL I, R, S, Kan, AMK, Z 1.0 
kanamycin (Kan), cycloserine (Cyc), rifabutin (Rfb), ethionamide (ETH), amikacin (AMK), capreomycin 
(Cap). 
Table 18. Minimal inhibitory concentration of ISO against susceptible and MDR-TB strains. 
3.2.2 Mechanism of action  
Similarly to what happens with Isoniazid, a substance used in  the first line treatment of TB, 
and with ethionamide, a second line drug, ISO strongly inhibits the synthesis of mycolic acids. 
However, ISO can also inhibit shorter chain fatty acid synthesis, thus producing an effect that 
had never been observed in other drugs  showing antimycobacterial properties (Phetsuksiri et 
al., 2003). 
ISO interferes in the fatty acid metabolism, through  inhibition of the ∆9 desaturase DesA3. 
This mechanism leads to the inhibition of the of oleic acid synthesis, which is the most 
abundant unsaturated fatty acid in Mycobacterium spp. and a constituent of mycobacterial 
membrane phospholipids. Due to the vital functions of oleic acid, the inhibition of its 
synthesis  leads to cell death. Another membrane phospholipid constituent which is 
indirectly affected during this pathway is the tuberculostearic acid, given that this substance 
is synthesized  through direct methylation of oleic acid by S-adenosylmethionine.   
ISO inhibitory mechanism  in mycolic acids synthesis has not been described. Nevertheless, 
it was already demonstrated that there is no relationship between oleic acid and mycolic 
acids synthesis inhibition (Phetsuksiri et al., 2003).  
Another relevant aspect involved in the ISO mechanism of action concerns the fact that  its 
activation by the flavin-containing monooxygenase EthA is  mandatory to trigger an activity 
against M. tuberculosis (Korduláková, 2007). Based on the LC/MS analyses of the 
compounds formed after ISO treatment  with the partially purified recombinant EthA 
(compounds 53, 55 and 57, Fig. 10), the  following activation pathway was proposed: 
Initially, oxidation reactions  with sulfur atom lead to the formation of intermediary 54, 
which undergoes an elimination reaction, yielding the formimidamide 55. Further reactions 
lead to the formation of carbodiimide 56, which can be hydrolyzed, yielding the urea 
derivative 57 (Fig. 10).  The data obtained from previous  studies with ETH and thiacetazone 
could suggest that ISO would be a prodrug, activated by oxidations reactions catalyzed by 
EthA, and that  carbodiimide 56  would appear as its active form. However, the real function 
of this process and its role in the inhibition of oleic acid and/or mycolic acids synthesis are 
not well understood. Besides, it is worthy  to consider that  EthA could  only serve to retain 
ISO or its metabolites inside the bacterial cell.  
www.intechopen.com
  
Global View of HIV Infection 
 
154 
N
H
S
N
H
R R
N
H
S
N
R ROH
N
H
S
N
R ROHO
N
H
N
R R
C NN
R
R
N
H
O
N
H
R R
EthA EthA
H2O
ISO 53 54
55
56
57
 
Fig. 10. Proposed pathway for ISO activation  by EthA. 
3.2.3 ISO analogues 
In spite of the interesting results shown by the prior clinical trials with ISO , this substance 
was found to present some pharmacokinetic disadvantages,  which  limited its clinical use 
as an antimycobacterial agent (Wang & Hickey, 2010).  In view of the above, and in an 
attempt to overcome this kind of inconvenient,  several ISO derivatives have been 
synthesized  throughout the last years, as may be illustrated by the following  examples.  
Phetsuksiri and  collaborators  described the antimycobacterial evaluation of  series of ISO 
analogues (Phetsuksiri et al., 1999). These compounds were prepared through random 
substitutions in the side chains attached to the thiourea nucleus, which it is required for 
animycobacterial activity (Phetsuksiri et al., 2003; Korduláková, 2007). This strategy  led to 
the formation of a pool of new ISO derivatives, which present variations both in the 
symmetric and asymmetric side chains with alkyl, alkoxy or sulfur fuctional groups 
substituted in para and para´ positions (Table 19). 
Said  results show  that the most part of derivatives presented a similar or a better  activity 
(MIC <0.1 to 2.5µg/mL), when compared to ISO (MIC= 2.0µg/mL).  Among some relevant 
aspects concerning SAR, it may be noted that  the replacement of oxygen (58-60)  by sulfur 
(62-64) in the side chain provides a considerable improvement in the antimycobacterial 
activity. Moreover, the introduction of a long alkyl chain plus an ester group leads to the 
formation of inactive compounds (67,68). Bulky groups, such as t-butyl, attached to para and 
para´ position of phenyl ring, also  gave rise to an inactive derivative (65). These results 
suggest that chemical modifications on  thiourea nucleus basis could lead to the constitution 
of an  inhibitor, that would be even more powerful against M. tuberculosis.  
In another study, Bhowruth and  collaborators (Bhowruth et al., 2006)  synthesized and 
evaluated  series of symmetrical and unsymmetrical ISO analogues  against M. tuberculosis 
(Table 20). Several compounds  disclosed by this study present  similar or better activities 
than ISO (MIC <0.1 to 1.56µg/mL). It is  worthy to mention that the introduction of an 
aliphatic C4 chain to either or both R1 and R2-positions increased the potency of the inhibitor 
(76-79, 81). Among them, the derivatives 78 and 79 were the most active, with a significant 
10-fold increase in potency against M. tuberculosis, when compared to ISO. 
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* MIC99 is defined as the lowest concentration of compound that reduced 99% of the number of M. 
tuberculosis colonies on the plates, in comparison with those at  the control plate free of compound. 
Table 19. ISO analogues prepared by Phetsuksiri and collaborators,  as well as their 
respective MIC values. 
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Table 20. Structures and antimycobacterial activity of ISO derivatives. 
Liav and collaborators investigated the effect of replacement of one of the isoamyloxyphenyl 
ISO moieties by a carbohydrate (Liav et al., 2008a). Said modification aimed at the 
production of ISO analogues with better hydrophilic properties, which could be useful to 
mitigate the inconvenient represented by the poor bioavailability of this drug (Fig.11). 
Among these compounds, only the arabinfuranosyl derivative 90 has a MIC value of 
2.5µg/mL, which is almost more potent than ISO. 
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Fig. 11. ISO derivatives containing carbohydrates moieties.  
This promising result  encouraged Liav and  collaborators (Liav et al., 2008b)  to synthesize 
and  evaluate the D-aldopentofuranosyl derivatives (90-93, Fig.12). Arabino analogue (90) 
was re-tested, and found to be  more potent than ISO, while the ribo analogue (91)  
presented a MIC value in the same range of ISO. The D-xylo analogue (92) was rather less 
active, and the D-lyxo product (93)  only acted at a concentration of 50µg/mL. These results 
could suggest that the products are very sensitive to  stereochemical configuration, thus 
indicating that  the carbohydrate group does not only add the required hydrophilicity to the 
molecule, being also responsible for adding  specificity to it. 
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Fig. 12. Other ISO derivatives containing carbohydrates moieties. 
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4. Conclusion 
Thiourea is a very important functional group for anti-HIV and anti-TB drug discovery,  
and, as seen above, literature has already described the promising biological activities of 
several derivatives. In the context of AIDS drug discovery, this scaffold is found in two 
remarkably important classes of compounds, namely among PETT and TIBO derivatives. 
The PETT compound TRV has been exploited as an excellent lead compound, whose  
several derivatives have been described. TIBO derivatives were essential for the 
development of NNRTI, a class of antiretroviral agents that currently present a relevant role 
in AIDS treatment.  In parallel, as refers to  TB drug discovery, ISO was found to present 
promising activities against resistant strains,  especially due to its unique mechanism of 
action. In  view of said data, the development of substances  containing thiourea moiety and 
showing a potential activity against both diseases  could be considered an important 
research field,  which should be particularly orientated towards the improvement  of 
therapeutic options for HIV-TB co-infected patients. 
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